What is BWAY's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.46B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BWAY?

P/E (TTM) is 53.64 and 52-week range is $2391.00 to $5123.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BWAY figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BWAY?

The company profile lists revenue (TTM) near $50M, net income (TTM) near $6M, EPS (TTM) near $0.23 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Brainsway Ltd based, and what identifiers does Chartloom list?

The company context section lists headquarters in Jerusalem, IL, 40.2M shares outstanding, ISIN IL0011007189 when available from company profile and filing metadata.

Brainsway Ltd

$BWAY

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

Browse other companiesFree AI scores and summaries for more stocks

Brainsway Ltd

$BWAY

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The firm primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

Employees

129

Website

www.brainsway.com/

IPO

2006-12-24

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

TEL AVIV STOCK EXCHANGE

ISIN

IL0011007189

Headquarters

Jerusalem, IL

Shares outstanding

40.2M

NAICS sector

Manufacturing

Institutional ownership

10.34%

Browse other companiesFree AI scores and summaries for more stocks

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The firm primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

Employees

129

Website

www.brainsway.com/

IPO

2006-12-24

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)